Victor Sapena
Overview
Explore the profile of Victor Sapena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ruiz-Garcia A, Pallares-Carratala V, Turegano-Yedro M, Torres F, Sapena V, Martin-Gorgojo A, et al.
Nutrients
. 2023 Apr;
15(8).
PMID: 37111028
Background: The impact of vitamin D supplementation on cardiovascular outcomes and mortality risk reduction remains unclear due to conflicting study findings. Methods: We conducted a systematic review and meta-analysis of...
12.
El Hajra I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, Mauro E, Llarch N, et al.
Hepatology
. 2023 Jan;
77(4):1139-1149.
PMID: 36632997
Background And Aims: Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival...
13.
Diaz-Gonzalez A, Hernandez-Guerra M, Perez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Diaz A, et al.
Hepatology
. 2023 Jan;
77(4):1095-1105.
PMID: 36626622
Background And Aims: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used...
14.
Hernandez-Rodriguez J, Duran-Sanclemente J, Prieto-Gonzalez S, Araujo O, Hospital-Vidal T, Casanovas G, et al.
Clin Drug Investig
. 2022 Sep;
42(11):949-964.
PMID: 36173596
Background: Unprotected and fragile elderly people in nursing homes experienced the highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic. Objective: Our aim was to study the role...
15.
Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, et al.
World J Hepatol
. 2022 Sep;
14(7):1438-1458.
PMID: 36158918
Background: Dermatologic adverse events (DAEs) are associated with a better outcome in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent received. The exact mechanisms associated with the development...
16.
Cruz-Ojeda P, Schmid T, Boix L, Moreno M, Sapena V, Praena-Fernandez J, et al.
Cells
. 2022 Sep;
11(17).
PMID: 36078082
Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification...
17.
Soria A, Calvo M, Casas M, Vidales Z, Munoz-Martinez S, Sapena V, et al.
Front Oncol
. 2022 Aug;
12:829483.
PMID: 35982971
Introduction: The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little...
18.
Munoz-Martinez S, Sapena V, Forner A, Bruix J, Sanduzzi-Zamparelli M, Rios J, et al.
Liver Int
. 2022 May;
42(8):1891-1901.
PMID: 35608939
Background & Aims: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk...
19.
Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mahringer-Kunz A, et al.
Hepatology
. 2022 Mar;
76(5):1318-1328.
PMID: 35349760
Background & Aims: The diagnostic accuracy of Liver Imaging Reporting and Data System (LI-RADS) v.2018 and European Association for the Study of the Liver (EASL) criteria for the diagnosis of...
20.
Cossiga V, Sanduzzi-Zamparelli M, Sapena V, Guarino M, Dallio M, Torrisi E, et al.
Front Pharmacol
. 2022 Feb;
13:824879.
PMID: 35185575
HCV eradication by direct-acting antivirals (DAAs) improves liver outcomes and reduces overall liver mortality. However, patients with advanced chronic liver disease (ACLD) may experience a progression of liver disease despite...